Obinutuzumab as bridging therapy for successful manufacturing of axicabtagene ciloleucel for transformed follicular lymphoma with circulating cells.
Mohamed A Kharfan-DabajaMichael D JainSonikpreet AulakhErnesto AyalaAbba C ZubairHan W TunHien D LiuFrederick L LockeJulio C ChavezPublished in: American journal of hematology (2019)